Erratum: A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer (Gene Therapy (2007) vol. 14 (1695-1704) 10.1038/sj.gt.3303036);A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer

Gene Therapy

Volumn 14, Issue 24, 2007, Pages 1695-1704

  Riezebos Brilman, A ^a   Walczak, M ^a   Regts, J ^a   Rots, M G ^b   Kamps, G ^b   Dontje, B ^a   Haisma, H Y ^b   Wilschut, J ^a   Daemen, T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; HYBRID PROTEIN; LUCIFERASE; PROTEIN E6; PROTEIN E7;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; DRUG EFFICACY; EFFECTOR CELL; FEMALE; FREQUENCY ANALYSIS; GENE CONSTRUCT; GENE EXPRESSION; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNIZATION; IMMUNOLOGICAL MEMORY; IN VIVO STUDY; LYMPHOCYTE DEPLETION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEMLIKI FOREST ALPHAVIRUS; STEM CELL; T LYMPHOCYTE; TRANSGENE; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENOVIRIDAE; HUMAN ADENOVIRUS TYPE 5; HUMAN PAPILLOMAVIRUS; MURINAE; MUS; PAPILLOMAVIRIDAE; RABBIT FIBROMA VIRUS; SEMLIKI FOREST VIRUS;

EID: 36949001361     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3303084     Document Type: Erratum

References (48)

1. Daemen T, Regts J, Holtrop M, Wilschut J. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Therapy 2002; 9: 85-94.
2. Daemen T, Riezebos-Brilman A, Bungener L, Regts J, Dontje B, Wilschut J. Eradication of established HPV16-transformed tumours after immunisation with recombhumt Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine 2003; 21: 1082-1088.
3. Daemen T, Riezebos-Brilman A, Regts J, Dontje B, van der Zee A, Wilschut J. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther 2004; 9: 733-742.
4. Riezebos-Brilman A, Regts J, Freyschmidt EJ, Dontje B, Wilschut J, Daemen T. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice. Gene Therapy 2005; 12: 1410-1414.
5. Riezebos-Brilman A, de Mare A, Bungener L, Huckriede A, Wilschut J, Daemen T. Recombinant alphaviruses as vectors for anti-tumour and ant-microbial immunotherapy. J Clin Virol 2006; 35: 233-243.
6. Bungener L, de Mare A, de Vries-Idema J, Sehr P, van der Zee A, Wilschut J et al. A virosomal immunization strategy against cervical cancer and pre-malignant cervical disease. Antivir Ther 2006; 11: 717-727.
7. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265.
8. Walboomers JM, Jacobs MV, Manos MM, Bosch EX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189: 12-19.
9. Doorbar J. The papillomavirus life cycle. J Clin Virol 2005; 32 (Suppl 1): S7-S15.
10. Munger K, Howley PM. Human papillomavirus immortalization and transformation functions. Virus Res 2002; 89: 213-228.
11. Eiben GL, Velders W, Kast WM. The cell-mediated immune response to human papillomavirus-induced cervical cancer: Implications for immunotherapy. Adv Cancer Res 2002, 86: 113-148.
12. Dummer R, Hassel JC, Fellenberg F, Eichmuller S, Maier T, Slos P et al. Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood 2004; 104: 1631-1638.
13. Nemunaitis J, Sterman D, Jablons D, Smith JW, Fox B, Maples P et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 2004; 96: 326-331.
14. Reid T, Warren R, Kirn D. Intravascular adenoviral agents in cancer patients: Lessons from clinical trials. Cancer Gene Ther 2002; 9: 979-986.
15. Jooss K, Yang Y, Fisher KJ, Wilson JM. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212-4223.
16. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004; 10: 616-629.
17. Nwanegbo, E, Vardas E, Gao W, Whittle H, Sun H, Rowe D et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004; 11: 351-357.
18. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, de Bethune MP et al. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: Efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 2003; 77: 8263-8271.
19. Shayakhmetov DM, Li ZY, Ni S, Lieber A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 2004; 78: 5368-5381.
20. St George JA. Gene therapy progress and prospects: Adenoviral vectors. Cene Therapy 2003, 10: 1135-1141.
21. Colmenero P, Berglund P, Kambayashi T, Biberfeld P, Liljestrom P, Jondal M. Recombinant Semliki Forest virus vaccine vectors: The route of injection determines the localization of vector RNA and subsequent T cell response. Gene Therapy 2001; 8: 1307-1314.
22. Sato Y, Shiraishi Y, Furuichi T. Cell specificity and efficiency of the Semliki forest virus vector- and adenovirus vector-mediated gene expression in mouse cerebellum. J Neurosci Methods 2004; 137 111-121.
23. Bronte V, Cingarlini S, Apollondi E, Serafini P, Marigo I, De Santo C et al. Effective genetic vaccination in with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase. J Immunol 2003; 171: 6396-6405.
24. Lin CT, Hung CF, Juang J, He L, Lin KY, Kim TW et al. Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol Ther 2003, 8: 559-566.
25. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194: 823-832.
26. Fitzgerald JC, Gao GP, Reyes-Sandoval A, Pavlakis GN, Xiang ZQ, Wlazlo AP et al. A simian replication-defective adenoviral recombinant vaccine to HTV-1 gag. J Immunol 2003; 170: 1416-1422.
27. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ et al. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004; 172: 6290-6297.
28. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ, Davies ME et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immuno-deficiency virus type 1 gag gene. J Virol 2003; 77: 6305-6313.
29. Berglund P, Fleeton MN, Smerdou C, Liljestrom P. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 1999; 17: 497-507.
30. Huckriede A, Burigener L, Holtrop M, de Vries J, Waarts BL, Daemen T et al. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: Indications for cross-priming. Vaccine 2004, 22: 1104-1113.
31. Chen M, Barnfield C, Naslund TI, Fleeton MN, Liljestrom P. MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells. J Virol 2005; 79: 2964-2972.
32. Fournier P, Zeng J, Schirrmacher V. Two ways to induce innate immune responses in human PBMCs: Paracrine stimulation of IFN-alpha responses by viral protein or dsRNA. Int J Oncol 2003; 23: 673-680.
33. Wang L, Smith D, Bot S, Dellamary L, Bloom A, Bot A. Noncoding RNA danger motifs bridge innate and adaptive immunity and are potent adjuvants for vaccination. J Clin Invest 2002; 110: 1175-1184.
34. Mercier S, Gahery-Segard H, Monteil M, Lengagne F, Guillet JG, Eloit M et al. Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product. J Virol 2002; 76: 2899-2911.
35. Tillman BW, de Gruijl TD, Luykx-de Bakker SA, Scheper RJ, Pinedo HM, Curiel TJ et al. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector. J Immunol 1999; 162: 6378-6383.
36. Rea D, Schagen FH, Hoeben RC, Mehtali M, Havenga MJ, Toes RE et al. Adenoviruses activate human dendritic cells without polarization toward a T-helper type 1-inducing subset. J Virol 1999; 73: 10245-10253.
37. de Gruijl TD, Ophorst OJ, Goudsmit J, Verhaagh S, Lougheed SM, Radosevic K et al. Intradermal delivery of adenoviral type-35 vectors leads to high efficiency transduction of mature, CD8+ T cell-stimulating skin-emigrated dendritic cells. J Immunol 2006; 177: 2208-2215.
38. Wherry EJ, Teichgraber V, Becker TC, Masopust D, Kaech SM, Antia R et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4: 225-234.
39. Lanzaveochia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005; 17: 326-332.
40. Gourley TS, Wherry EJ, Masopust D, Ahmed R. Generation and maintenance of immunological memory. Semin Immunol 2004; 16: 323-333.
41. Visser J, van Baarle D, Hoogeboom BN, Reesink N, Klip H, Schuuring E et al. Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia. Int J Cancer 2006; 118: 2529-2537.
42. + regulatory T cells are increased in cervical cancer patients and suppress T cell responses against human papilloma virus 16 E6 and E7. Clin Exp Immunol 2007; in press.
43. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16- transformed cells. Eur J Immunol 1993; 23: 2242-2249.
44. van der Burg SH, Kwappenberg KM, O'Neill T, Brandt RM, Melief CJ, Hickling JK et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001; 19: 3652-3660.
45. Ji H, Chang EY, Lin KY, Kurman RJ, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.
46. Gommans WM, van Eert SJ, McLaughlin PM, Harmsen MC, Yamamoto M, Curiel DT et al. The carcinoma-specific epithelial glycoprotein-2 promoter controls efficient and selective gene expression in an adenoviral context. Cancer Gene Ther 2006; 13: 150-158.
47. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509-2514.
48. Alemany R, Curiel DT. CAR-binding ablation does not change biodistribution and toxicity of adenovirus vectors. Gene Therapy 2001; 8: 1347-1353.